Arena Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced the resignation of Robert Hoffman, vice president, finance and chief financial officer (CFO). Hoffman, who has accepted a new position in the healthcare industry, will remain in his current role at Arena until the reporting of the company’s year-end results and the filing of the Form 10-K for the year ended 31 December 2010.
In the interim, Jennifer Bielasz, senior director of accounting and controller, and Carolyn Felzer, senior director of finance, will continue to play key roles in Arena’s finance department. Bielasz joined Arena in 2001 and is responsible for managing all accounting, stock administration and tax compliance activities. Previously, she served as the controller of both public and private companies, including as vice president and controller of Guild Mortgage Company.
Felzer joined Arena in 2006 and is responsible for public reporting, Sarbanes-Oxley (SOX) compliance, 401(k) and other administrative functions. Prior to joining Arena, she served as senior director of finance and administration at Salmedix, until its acquisition by Cephalon, and as corporate secretary and vice president and controller at Corvas International, until its acquisition by Dendreon.
Bielasz and Felzer both began their careers at KPMG.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.